文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

寡转移性子宫内膜癌转移灶导向放疗的疗效与预后因素

Treatment Outcomes and Prognostic Factors of Metastasis-Directed Radiation Therapy for Oligometastatic Endometrial Cancer.
PubMed 文献 · Adv Radiat Oncol · 2026-04-15

该回顾性研究分析了101例(203个病灶)寡转移性子宫内膜癌患者接受转移灶导向放疗(MDRT)的结局与预后因素。中位随访36.4个月,3年总生存率76.3%、无进展生存率24.5%,2年局部无失败生存率64.7%。有利的寡转移分类、子宫内膜样组织学、有利的放疗反应及最大剂量≥40 Gy与总生存改善独立相关,仅1例3级毒性。

要点

  • MDRT在寡转移性子宫内膜癌中取得较好的3年总生存率(76.3%)
  • 有利寡转移分类、子宫内膜样组织学、放疗反应和最大剂量≥40 Gy与OS改善独立相关
  • 重复MDRT较单次疗程显示出OS改善趋势,但需前瞻性验证

核心结论

  • MDRT在寡转移性子宫内膜癌中产生有利结局,寡转移分类、组织学和放疗反应是主要预后因素。
  • MDRT可作为多学科框架下新发和复发性寡转移的可行选择,但需前瞻性多中心研究验证。

研究设计与样本

  • 回顾性分析2015年至2025年间101例(203个病灶)≤5个转移灶的寡转移性子宫内膜癌患者,均接受MDRT。
  • 寡转移状态按欧洲放射肿瘤学会-欧洲癌症研究与治疗组织框架分类,采用多变量Cox回归评估预后因素,毒性按CTCAE v5.0分级。

主要发现

  • 中位随访36.4个月时,3年OS、PFS和2年局部无失败生存率分别为76.3%、24.5%和64.7%。
  • 多变量分析显示有利寡转移分类、子宫内膜样组织学、有利放疗反应和最大剂量≥40 Gy(EQD2,α/β=10)与OS改善独立相关。
  • 除组织学外,其他因素对PFS均显著;倾向性匹配分析中重复MDRT较单次疗程显示OS改善趋势。
  • 仅发生1例3级毒性事件,无≥4级毒性。

关键数值与推荐

  • 最大剂量≥40 Gy(等效剂量按2 Gy分次,α/β=10)与改善OS独立相关。
  • 有利寡转移疾病分类、子宫内膜样组织学、有利放疗反应与改善OS独立相关,除组织学外上述因素对PFS也显著。

临床怎么用

  • 对于≤5个转移灶的寡转移性子宫内膜癌,可考虑在多学科框架下实施MDRT。
  • 放疗计划应尽量达到最大剂量≥40 Gy(EQD2,α/β=10)以改善生存。
  • 对复发性寡转移可考虑重复MDRT,但需前瞻性研究确认。

局限性

  • 回顾性研究设计,样本量有限(101例),存在选择偏倚可能。
  • 重复MDRT的OS改善仅为趋势,未达统计学显著,需前瞻性多中心研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate outcomes and prognostic factors associated with metastasis-directed radiation therapy (MDRT) for oligometastatic endometrial cancer. METHODS AND MATERIALS: We retrospectively analyzed 101 patients (203 lesions) with ≤5 metastatic lesions treated with MDRT between 2015 and 2025. Oligometastatic states were classified according to the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer framework. Endpoints were overall survival (OS), progression-free survival (PFS), and local failure-free survival. Prognostic factors were assessed using multivariable Cox regression, and toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. RESULTS: At a median follow-up of 36.4 months, 3-year OS, PFS, and 2-year local failure-free survival rates were 76.3%, 24.5%, and 64.7%, respectively. Multivariable analyses revealed that favorable oligometastatic disease classification, endometrioid histology, favorable radiation therapy (RT) response, and maximum dose ≥40 Gy (equivalent dose in 2 Gy fractions, α/β = 10) were independently associated with improved OS. All factors, except for histology, were significant for PFS. In a propensity-matched analysis, repeated MDRT for recurrent oligometastases showed a trend toward improved OS compared with a single course. One grade 3 event occurred with no grade ≥4 toxicity. CONCLUSIONS: MDRT yielded favorable outcomes in oligometastatic endometrial cancer. Oligometastatic classification, histology, and RT response were major prognostic factors. MDRT may be a viable option within a multidisciplinary framework for de novo and recurrent oligometastases, but validation in prospective multicenter studies is warranted.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lee WH, Kim YB. Treatment Outcomes and Prognostic Factors of Metastasis-Directed Radiation Therapy for Oligometastatic Endometrial Cancer. Adv Radiat Oncol. 2026. PMID: 42206293. doi:10.1016/j.adro.2026.102058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。